Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

por Michiko Asano, Hiroshi Okada, Yohji Itoh, Hajime Hirata, Kensuke Ishikawa, Erika Yoshida, Akiko Matsui, Elizabeth J. Kelly, Kathryn Shoemaker, Urban Olsson, Johan Vekemans
Publicado 2022